GlobeNewswire Press

  1. I-Mab Biopharma And TRACON Pharmaceuticals Announce Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of The CD73 Antibody TJD5 In Patients With Advanced Solid Tumors 8/1/2019

    I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, and TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today jointly announced that TRACON has dosed the first patient in a U.S. Phase 1 first-in-human clinical trial of I-Mab’s proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors (NCT identifier number: NCT03835949).

  2. Xynomic Received China Approval To Start 2 Pivotal Lymphoma Clinical Trials 7/30/2019

    Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced that Xynomic has received approval from China’s National Medical Products Administration (“NMPA”) to start two pivotal clinical trials in China. In these two trials, Xynomic will test its lead drug candidate abexinostat (as a single agent) as a third-line treatment of diffuse large B-cell lymphoma (“DLBCL”) and as a third-line treatment of follicular lymphoma (“FL”), respectively.

  3. Hepion Pharmaceuticals Receives FDA Authorization To Proceed With IND Opening Study Of CRV431 For NASH 7/29/2019

    Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that the U.S. Food and Drug Administration (“FDA”) has reviewed its Investigational New Drug (“IND”) application for CRV431 for the treatment of NASH and has authorized that the Company proceed with its planned IND opening study.

  4. Spring Bank Announces FDA Acceptance Of IND Application For SB 11285, An IV-Administered STING Agonist, For The Treatment Of Advanced Solid Tumors 7/29/2019

    Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, announced that its Investigational New Drug (IND) application for a Phase 1 trial of SB 11285, the company’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist development candidate, is now effective following clearance by the FDA.

  5. Rhythm Pharmaceuticals Announces Positive Opinion By The European Medicines Agency On Orphan Drug Designation For Setmelanotide For The Treatment Of Bardet-Biedl Syndrome 7/29/2019

    Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending setmelanotide for designation as an orphan medicinal product for the treatment of patients with Bardet-Biedl syndrome (BBS).

  6. VBI Vaccines Announces Dosing Of First Recurrent GBM Patient In Part B Of Ongoing Phase 1/2a Study Of VBI-1901 7/29/2019

    VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the first patient has been dosed in Part B of the ongoing Phase 1/2a clinical study of VBI-1901, VBI’s oncology immunotherapeutic, in recurrent glioblastoma (GBM) patients.

  7. TYME Technologies Announces New Collaboration With NYU Langone To Advance TYME's Cancer Metabolism-Based Therapy, SM-88 7/29/2019

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company, announced a new research collaboration with NYU Langone Health to advance the development of innovative treatments for patients with metastatic cancers, including pancreatic cancer.

  8. Salarius Pharmaceuticals Enrolls First Patient In A Phase 1 Clinical Study Of Its Novel Inhibitor Targeting Epigenetics In Patients With Advanced Solid Tumors 7/22/2019

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has enrolled the first patient in a Phase 1 clinical study of the company’s lead compound, Seclidemstat, in patients with advanced solid tumors resistant to standard-of-care therapies. 

  9. Predictive Oncology Subsidiary Helomics Collaborates With UPMC To Establish A Data And Artificial Intelligence-Driven Approach To Treating Ovarian Cancer 7/18/2019

    Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, today announced a joint collaborative agreement with UPMC to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients.

  10. Adaptimmune Starts The SURPASS Clinical Trial With Its First Next-Generation SPEAR T-cells Targeting MAGE A4 To Enhance Antitumor Responses 7/18/2019

    Adaptimmune Therapeutics plc, Philadelphia, PA, and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated SURPASS, its first clinical trial with a next-generation SPEAR T-cell targeting MAGE-A4.